Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.

about

Lopinavir protein binding in HIV-1-infected pregnant women.Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN.Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats.

P2860

Q33869395-3373A761-0472-4451-BC65-00194ED85EDC Q37973439-13B6EED6-00DA-45F7-8256-BBDC643A3B9B Q50280080-00B7F8F0-05D7-4342-B086-B9C02CA4B439

P2860

Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.

Item

http://www.wikidata.org/entity/Q46731853

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Characterization of nelfinavir ...... rug displacement interactions.

@en

Characterization of nelfinavir ...... rug displacement interactions.

@nl

type

Item

label

Characterization of nelfinavir ...... rug displacement interactions.

@en

Characterization of nelfinavir ...... rug displacement interactions.

@nl

prefLabel

Characterization of nelfinavir ...... rug displacement interactions.

@en

Characterization of nelfinavir ...... rug displacement interactions.

@nl

P1476

Characterization of nelfinavir ...... rug displacement interactions.

@en

P2093

Au S

http://www.w3.org/2001/XMLSchema#string

Aweeka FT

http://www.w3.org/2001/XMLSchema#string

Chi J

http://www.w3.org/2001/XMLSchema#string

Jayewardene AL

http://www.w3.org/2001/XMLSchema#string

Motoya T

http://www.w3.org/2001/XMLSchema#string

Stone JA

http://www.w3.org/2001/XMLSchema#string

Thevanayagam LN

http://www.w3.org/2001/XMLSchema#string

P2860

Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities

Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins

Nelfinavir mesylate: a protease inhibitor.

Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.

In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.

Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.

Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization.

The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.

Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.

Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.

P304

122-128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1468-1293.2006.00356.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Terrence F. Blaschke

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7352843

http://www.w3.org/2001/XMLSchema#string

P698

16420257

http://www.w3.org/2001/XMLSchema#string

Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.

about

P2860

P2860

Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698